It is well established that infiltrative renal masses (IRMs) are mostly malignant and aggressive. Yet, until recently, the standard practice in radiology hasn’t been to routinely assess or document IRMs. To better understand the prevalence and significance of IRMs, researchers in the Glickman Urological & Kidney Institute led a new and revealing investigation.
These three genetic models could help refine recurrence risk and guide treatment decisions for patients with renal cell carcinoma.
Pembrolizumab plus axitinib is another effective option for treating renal cell carcinoma, indicates the KEYNOTE-426 study.
A case series reviewing Cleveland Clinic’s nearly 30 years of surgical experience with radical nephrectomy and inferior vena cava thrombectomy provides a wealth of information regarding thrombus level, operative technique, outcomes and complications.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Staggering results in this phase 3 trial point to the future of care for advanced renal cell carcinoma.
This study confirms the assay’s validity and provides the required level 1B evidence needed for inclusion in treatment guidelines.
Research shows targeted therapies along with stereotactic radiosurgery increase survival in patients with metastatic renal cell carcinoma. But what about for patients with brain metastases?
Intermittent sunitinib dosing does not compromise clinical efficacy and is feasible in patients with previously untreated metastatic renal cell carcinoma, according to a phase 2 Cleveland Clinic study.
Cleveland Clinic research demonstrates the presence of the PD-1/PDL-1 ligand-receptor complex on myeloid-derived suppressor cells within renal tumors, suggesting that checkpoint inhibitors could be effective immunotherapy in renal cell carcinoma.
The challenging extraction of level III inferior vena cava (IVC) thrombi related to a renal neoplasm typically requires open surgery. But early experience at Cleveland Clinic shows a robot-assisted approach is feasible and has potential benefits in appropriate patients.